Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)

OBJECTIVE: There is no standard care for advanced non–small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yong, Wu, Yi-Long, Cao, Le-Jie, Chen, Jian-Hua, Ma, Zhi-Yong, Cui, Jiu-Wei, Wang, Jie, Liu, Hong-Bing, Ding, Jing-Yan, Hu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles: Thoracic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493697/
https://www.ncbi.nlm.nih.gov/pubmed/30950859
http://dx.doi.org/10.1097/COC.0000000000000538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493697/
https://www.ncbi.nlm.nih.gov/pubmed/30950859
http://dx.doi.org/10.1097/COC.0000000000000538

Ejemplares similares